Ascendis Pharma A/S (ASND)
After hours:
| Previous Close | 122.64 |
| Open | 124.22 |
| Bid | 129.59 x 100 |
| Ask | 130.17 x 100 |
| Day's Range | 123.51 - 130.27 |
| 52 Week Range | 90.13 - 161.00 |
| Volume | |
| Avg. Volume | 635,493 |
| Market Cap | 7.757B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.86 |
| Earnings Date | Feb 05, 2025 - Feb 10, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 181.98 |
GlobeNewswireAscendis Pharma Reports Third Quarter 2024 Financial Results
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025 – SKYTROFA Q3 revenue of €47.2 million – 60%+ year-over-year volume growth offset by current and prior period sales deductions – Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be €200 - €220 million, and fu
- GlobeNewswire
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on November 14, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2024 financial results. Those who would like to participate may access the live webca
